Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy

Deltenre, Pierre; Moreno, Christophe; Tran, Annelise; Ollivier, Isabelle; Provôt, F; Stanke, Françoise; Lazrek, Mouna; Castel, Hélène; Canva, V.; Louvet, Alexandre; Colin, Michel; Glowacki, François; Dharancy, Sébastien; Henrion, Jean; Hazzan, Marc; Noël, Christian; Mathurin, Philippe

doi:10.1111/j.1365-2036.2011.04741.x

Cited by 27 publications

(19 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Limited data exist about combination antiviral therapy (conventional or pegylated IFN plus ribavirin) in CKD stages 3–5 patients. Some information about the use of monotherapy with pegylated interferon in dialysis populations exists [82–87], and the available data on combined therapy (conventional or pegylated IFN plus ribavirin) in the CKD population derive mostly from studies of patients on maintenance haemodialysis [88–96]. There is limited information on the clearance of IFN in patients with CKD stages 3 and 4.…”

Section: Antiviral Treatment Of Hcv In Chronic Kidney Disease: Recmentioning

confidence: 99%

“…Combination antiviral therapy (IFN plus ribavirin) has not been recommended in prior guidelines [98]. According to preliminary findings [88–96], ribavirin should be used in patients on maintenance haemodialysis in a cautious and well-monitored setting. Ribavirin use, indeed, is limited by haemolytic anaemia that can be particularly dangerous in patients with chronic kidney disease, who often have anaemia as well as other comorbidities (e.g., cardiac ischemia) at baseline.…”

Section: Antiviral Treatment Of Hcv In Chronic Kidney Disease: Recmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C Virus Infection and Dialysis: 2012 Update

Fabrizi

2013

ISRN Nephrology

View full text Add to dashboard Cite

Hepatitis C virus infection is still common among dialysis patients, but the natural history of HCV in this group is not completely understood. Recent evidence has been accumulated showing that anti-HCV positive serologic status is significantly associated with lower survival in dialysis population; an increased risk of liver and cardiovascular disease-related mortality compared with anti-HCV negative subjects has been found. According to a novel meta-analysis (fourteen studies including 145,608 unique patients), the adjusted RR for liver disease-related death and cardiovascular mortality was 3.82 (95% CI, 1.92; 7.61) and 1.26 (95% CI, 1.10; 1.45), respectively. It has been suggested that the decision to treat HCV in patients with chronic kidney disease be based on the potential benefits and risks of therapy, including life expectancy, candidacy for kidney transplant, and co-morbidities. According to recent guidelines, the antiviral treatment of choice in HCV-infected patients on dialysis is mono-therapy but fresh data suggest the use of modern antiviral approaches (i.e., pegylated interferon plus ribavirin). The summary estimate for sustained viral response and drop-out rate was 56% (95% CI, 28–84) and 25% (95% CI, 10–40) in a pooled analysis including 151 dialysis patients on combination antiviral therapy (conventional or pegylated interferon plus ribavirin).

show abstract

Section: Antiviral Treatment Of Hcv In Chronic Kidney Disease: Recmentioning

confidence: 99%

Section: Antiviral Treatment Of Hcv In Chronic Kidney Disease: Recmentioning

confidence: 99%

Hepatitis C Virus Infection and Dialysis: 2012 Update

Fabrizi

2013

ISRN Nephrology

View full text Add to dashboard Cite

show abstract

“…They reported lower ribavirin serum concentrations in the first month of therapy for 1000 mg receiving group which disappeared later. At the end of the study, a positive correlation was detected between the first month ribavirin serum concentration and SVR rates and a dose of 1400 mg/week ribavirin was offered as optimal for hemodialysis patients [5] .…”

Section: Discussionmentioning

confidence: 93%

“…Previous studies have indicated that EPO dose may be increased up to 90.000 IU/week in order to prevent ribavirin induced anemia [5] . Due to some cost and payment restrictions, (according to social insurance instructions) EPO could be described as 15.000 IU/week in the presented patient.…”

Section: Discussionmentioning

confidence: 99%

“…Chronic HCV infection has been proved to be an independent risk factor over mortality of hemodialysis patients [4] . It has also been shown that post transplantation allograft nephropathy and diabetes mellitus are more commonly seen complications for chronic renal failure (CRF) in patients suffering from chronic HCV infection [5] . For transplantation cases, interferon (IFN) treatments are not recommended as they increase the risk of allograft rejection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sustained Virologic Response with Triple Therapy in a Hemodialysis Patient with Chronic HCV Infection

Kaygusuz¹,

Gül²,

Gülhan³

2014

Mediterr J Infect Microb Antimicrob

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is more prevalent and has been proven to be an independent risk factor over mortality among hemodialysis patients than normal population. Since sustained virologic response (SVR) is so beneficial and may be maintained in 90-100% of post-transplant cases, treatment of chronic HCV infection is strongly suggested for all patients undergoing renal transplantation. A 45-year-old male patient had been offered to have renal transplantation due to chronic renal failure, and referred to our clinic because of chronic HCV infection (HCV-RNA positive). He had received hemodialysis three times a week since 2007. The patient was diagnosed with chronic HCV infection fifteen years ago and was given a 48-week lasting IFN therapy in 2000 and a subsequent therapy of PEG-IFN-α2a for 48 weeks in 2004. Although both therapies had yielded end of treatment responses, subsequent relapses occurred. The patient was given a combination treatment involving PEG-IFN-α2a (135 μg/wk) for 24 weeks and ribavirin (200 mg/day) for 24 weeks and telaprevir (3 x 750 mg) for the first 12 weeks, and a weekly control visit in our clinic. The therapy was generally well tolerated and SVR was achieved. Triple therapy might be used as a treatment option in hemodialysis patients with genotype 1 chronic HCV infections.

show abstract

Infección por el virus de la hepatitis C en pacientes con enfermedad renal crónica

Carrión

Martín

2013

Clinical Liver Disease

View full text Add to dashboard Cite

show abstract

Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy

Abstract: SUMMARY BackgroundIn end-stage renal disease (ESRD) patients, hepatitis C virus (HCV) eradication improves patient and graft survival.

Cited by 27 publications

References 36 publications

Hepatitis C Virus Infection and Dialysis: 2012 Update

Hepatitis C Virus Infection and Dialysis: 2012 Update

Sustained Virologic Response with Triple Therapy in a Hemodialysis Patient with Chronic HCV Infection

Infección por el virus de la hepatitis C en pacientes con enfermedad renal crónica

Contact Info

Product

Resources

About